Navigation Links
SRI International Awarded a Department of Defense 'Laboratory-Clinical Transition' Grant to Advance SRI's Novel Anticancer Agents for Prostate Cancer Treatment
Date:10/13/2009

MENLO PARK, Calif., Oct. 13 /PRNewswire/ -- SRI International, an independent, nonprofit research and development organization, announced today that it has been awarded a $1.55M U.S. Department of Defense/Prostate Cancer Research Program (DoD/PCRP) grant to support product-driven, preclinical studies of SRI's novel agents that have the potential to become prostate cancer drugs. The goal of the program is to discover treatments that can revolutionize the prevention, detection, or treatment of prostate cancer.

Prostate cancer is the most commonly diagnosed cancer in men and second only to lung cancer as a leading cause of cancer deaths in men. There is currently no cure for advanced or metastatic prostate cancer. The available treatments for localized prostate cancer often leave patients with uncertainty about disease recurrence and complications such as incontinence or impotence. SRI researchers are working to develop an effective and well-tolerated therapy that improves prospects for a cure without impairing overall well-being.

With support from an earlier DoD/PCRP Idea Development Award, SRI researchers developed a novel class of anticancer drugs derived from dietary indoles found in cruciferous vegetables that prevent prostate tumor cell proliferation, progression, and invasion. The novel lead compound, SR13654, shows antitumor activity and disease control with few side effects at efficacious doses. Early preclinical safety studies indicate that this class of bis-indole compounds holds potential to be better tolerated than many anticancer agents currently on the market.

"This award will support SRI's efforts to continue the research and development of SRI's advanced lead, which holds promise for the treatment and prevention of prostate cancer," said Ling Jong, Ph.D., principal investigator and medicinal chemistry program director in SRI's Center for Cancer Research. "The successful development of this class of drug will fill a significant unmet need in current cancer therapy."

SRI researchers have experience moving new drug candidates from the laboratory bench to clinical testing and onto the marketplace. Through collaboration with the National Cancer Institute, SR13668, another compound derived from the bis-indole platform works as an Akt pathway inhibitor and has already advanced to human clinical trials for cancer prevention.

SRI's Center for Cancer Research, comprised of biologists and medicinal chemists with expertise in fundamental and applied cancer research, focuses on the study of tumor microenvironment, tumor metabolism, and aberrant signaling pathways that cause cancer. Through collaborative partnerships, SRI's Center for Cancer Research has been successful in generating an extensive drug pipeline translating discoveries into beneficial treatments.

About SRI's Biosciences Division

SRI's Biosciences division carries out basic research, drug discovery, and drug development, and provides contract services. SRI has all of the resources necessary to take R&D from "idea to IND"(TM) - from initial discovery to the start of human clinical trials - and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and other clients and partners advance well over 100 drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International

Silicon Valley-based SRI International is one of the world's leading independent research and technology development organizations. SRI, which was founded by Stanford University as Stanford Research Institute in 1946 and became independent in 1970, has been meeting the strategic needs of clients and partners for more than 60 years. Perhaps best known for its invention of the computer mouse and interactive computing, SRI has also been responsible for major advances in networking and communications, robotics, drug discovery and development, advanced materials, atmospheric research, education research, economic development, national security, and more. The nonprofit institute performs sponsored research and development for government agencies, businesses, and foundations. SRI also licenses its technologies, forms strategic alliances, and creates spin-off companies. In 2008, SRI's consolidated revenues, including its wholly owned for-profit subsidiary, Sarnoff Corporation, were approximately $490 million.

SOURCE SRI International


'/>"/>
SOURCE SRI International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Editor Named for International Journal Of Nursing Terminologies & Classifications
2. International Study Finds New Best Practices to Reduce Fire Casualties
3. MedicAlert Foundation International and CAP STS Collaborate to Standardize Emergency Medical Information
4. Medical Travel Company Satori World Medical Announces Relationship with Managing General Underwriter GreenWood International Insurance Services (GWI)
5. Sogo Photographs for a Cause Founder Wins Place in International Exhibition
6. International LDN Awareness Week, October 19 - 25th, 2009
7. International Experts to Review State-of-the-Art Thinking on Signal Detection and Data Mining
8. Profiles International Finds High Employee Utilization is One Key to Maximizing Productivity
9. Temps Inc. Acquires Medical Concepts Staffing Business From Analysts International Corporation
10. Director of UT Southwestern center honored with first international neurology medal
11. Hong Kong International Media Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: